Asia's Premier Pharma Event to Highlight Innovations in Drug Delivery Excipients from June 24-26 in Shanghai
Xi'an DELI Biochemical Industry Co., Ltd., a leader in pharmaceutical excipients, will unveil its cutting-edge Hydroxypropyl betadex (HP-β-CD) and Betadex Sulfobutyl Ether Sodium (SBECD) technologies at CPHI China 2025 (Booth E3Q10). These cyclodextrin derivatives are pivotal in enhancing drug solubility, stability, and bioavailability, addressing critical challenges in novel drug formulation—especially for injectables, oncology, and veterinary drugs. The event, Asia’s largest pharmaceutical gathering, convenes at Shanghai New International Expo Centre (SNIEC) from June 24-26.
Amid rising demand for complex drug delivery systems, Xi'an DELI’s cyclodextrin platforms offer transformative solutions:
Hydroxypropyl Betadex: Enables low-toxicity solubilization of poorly water-soluble APIs, accelerating development of oral and injectable generics and new molecular entities.
Betadex Sulfobutyl Ether Sodium: Provides high biocompatibility for parenteral formulations (e.g., antibiotics, antivirals), reducing renal toxicity and supporting extended-release profiles.
These excipients align with CPHI's focus on "New Quality Productivity," empowering drugmakers to overcome bioavailability barriers and streamline regulatory pathways for global markets.
Closing Invitation:
Xi'an Deli Biochemical Industry Co.,Ltd. Is a high-tech enterprise specializing in research & development, production & sales of cyclodextrin and its derivatives.
Since its establishment on August 27, 1999, the company has been adhering to the quality Policy of "focusing on accessories, quality first, sincere service, striving for first-class". After more than 20 years of hard work and development, the company currently has products DELI Brand Hydroxypropyl Betadex, DELI Brand Betadex Sulfobutyl Ether Sodium. The above products have been registered and filed with the FDA.
As cyclodextrins redefine drug delivery efficacy, CPHI offers the ideal stage to demonstrate their impact, and we invite partners to Booth E3Q10 to explore how hydroxypropyl betadex and Betadex Sulfobutyl Ether Sodium can transform your pipeline.”
For more information:
Visit: CPHI China 2025, June 24-26, SNIEC Shanghai, Booth E3Q10
Explore: DELI’s full cyclodextrin portfolio athttps://www.delicydextrin.com/
About Xi'an DELI Biochemical Industry Co., Ltd.
Specializing in high-performance pharmaceutical excipients since 2005, DELI pioneers cyclodextrin-based solutions for global drug innovators, adhering to USP/EP/ChP standards. Its products enable safer, more effective therapeutics across oncology, injectables, and targeted delivery.
About CPHI China 2025:
Co-located with PMEC China, this flagship event (E1-E7, W1-W5 Halls) covers drug ingredients, machinery, packaging, and biopharma, featuring 100+ conferences and international buyer delegations.
